Literature DB >> 15475838

A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling.

Narutaka Ohashi1, Hideo Mitamura, Kojiro Tanimoto, Yukiko Fukuda, Osamu Kinebuchi, Yasuo Kurita, Akiko Shiroshita-Takeshita, Shunichiro Miyoshi, Motoki Hara, Seiji Takatsuki, Satoshi Ogawa.   

Abstract

Calcium overload plays a key role in the development of atrial electrical remodeling. The effect of an L-type Ca channel blocker in preventing this remodeling has been reported to be short lasting, partly due to down-regulation of this channel and persisting Ca entry through the T-type Ca channel. To prove if efonidipine, a dual L- and T-type Ca channel blocker exerts a greater effect than an L-type Ca channel blocker verapamil, 21 dogs underwent rapid atrial pacing at 400 bpm for 14 days, pretreatment with efonidipine in 7 (E), verapamil in 7 (V), and none in 7 (C). We measured the atrial effective refractory period (ERP) serially during 14 days of rapid pacing. In response to rapid pacing, ERP decreased progressively in C. In contrast, in E and V, ERP remained greater than ERP in C (P < 0.01) on days 2 through 7. However, on the 14th day, ERP in V decreased to the level seen in C, whereas ERP in E remained significantly longer than ERPs in C or V (P < 0.01). The blockade L-type Ca channel alone is not sufficient, but the addition of a T-type Ca channel blockade shows a more sustained effect to prevent atrial electrical remodeling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475838     DOI: 10.1097/01.fjc.0000138163.11612.7b

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

Authors:  Narutaka Ohashi; Hideo Mitamura; Satoshi Ogawa
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 2.  Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update.

Authors:  Richard Gordan; Suwakon Wongjaikam; Judith K Gwathmey; Nipon Chattipakorn; Siriporn C Chattipakorn; Lai-Hua Xie
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 3.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

4.  Mechanisms Underlying AF: Triggers, Rotors, Other?

Authors:  David E Krummen; Shrinivas Hebsur; Jon Salcedo; Sanjiv M Narayan; Gautam G Lalani; Amir A Schricker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-04

5.  Cardiomyocyte Ca2+ overload in atrial tachycardia: is blockade of L-type Ca2+ channels a promising approach to prevent electrical remodeling and arrhythmogenesis?

Authors:  Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12       Impact factor: 3.000

6.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

7.  Presence and function of stress granules in atrial fibrillation.

Authors:  Guo Dong; Fengying Liang; Bo Sun; Chengcheng Wang; Yangyang Liu; Xiangpeng Guan; Bo Yang; Chunhong Xiu; Ning Yang; Fengyu Liu; Tianyi Lu; Wei Han
Journal:  PLoS One       Date:  2019-04-03       Impact factor: 3.240

8.  Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report.

Authors:  Xiaoou Wang; Yanxia Lin; Ling Chen; Dongke Liang; Jie Lin; Guoxian Qi; Wen Tian
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

9.  The mineralocorticoid receptor leads to increased expression of EGFR and T-type calcium channels that support HL-1 cell hypertrophy.

Authors:  Katharina Stroedecke; Sandra Meinel; Fritz Markwardt; Udo Kloeckner; Nicole Straetz; Katja Quarch; Barbara Schreier; Michael Kopf; Michael Gekle; Claudia Grossmann
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.